Biopharmaceutical Contract Manufacturing Market Size, Share, Trends, Growth Outlook

Biopharmaceutical Contract Manufacturing Market is estimated to increase at a Compounded Annual Growth Rate of 8.3% CAGR over the forecast period from 2024 to 2030

The Biopharmaceutical Contract Manufacturing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi & Molecular Therapy, Biosimilars), By Source (Mammalian, Non-Mammalian), By Service (Process Development, Fill And Finish Operations, Analytical And QC Studies, Packaging), By Application (Clinical, Commercial).

An Introduction to Biopharmaceutical Contract Manufacturing Market in 2024

In 2024, the market for biopharmaceutical contract manufacturing services addresses the outsourcing needs of biotechnology companies, pharmaceutical manufacturers, and academic institutions involved in the development and production of biologically derived therapeutics, including monoclonal antibodies, recombinant proteins, and cell-based therapies. Biopharmaceutical contract manufacturing organizations (CMOs) offer a wide range of services, including cell line development, process optimization, and cGMP manufacturing, to support preclinical research, clinical trials, and commercial-scale production of biopharmaceutical products. With a focus on flexibility, scalability, and regulatory compliance, biopharmaceutical CMOs provide customized solutions for every stage of the drug development lifecycle, from early-phase development and technology transfer to late-stage manufacturing and commercialization. Moreover, with advancements in single-use bioreactor systems, continuous manufacturing platforms, and digital supply chain management, the biopharmaceutical contract manufacturing market offers streamlined workflows, accelerated timelines, and cost-effective solutions for bringing biologic drugs to market, driving innovation and efficiency in the biopharmaceutical industry.

Market Trend: Increased Outsourcing by Pharmaceutical Companies

A significant trend in the biopharmaceutical contract manufacturing market is the increased outsourcing of manufacturing activities by pharmaceutical companies. With the growing complexity of biopharmaceutical products, coupled with the need for flexibility, cost-effectiveness, and regulatory compliance, pharmaceutical companies are increasingly turning to contract manufacturing organizations (CMOs) to handle the production of biologic drugs. Outsourcing manufacturing allows pharmaceutical companies to focus on their core competencies, such as research, development, and commercialization, while leveraging the specialized expertise, infrastructure, and scale of CMOs to meet their manufacturing needs. This trend reflects a strategic shift towards a more collaborative and agile manufacturing model in the biopharmaceutical industry, driving market growth and expansion in the biopharmaceutical contract manufacturing segment.

Market Driver: Rising Demand for Biologic Drugs and Biosimilars

A key driver for the biopharmaceutical contract manufacturing market is the rising demand for biologic drugs and biosimilars worldwide. Biologic drugs, including monoclonal antibodies, recombinant proteins, and cell-based therapies, represent a growing segment of the pharmaceutical market, driven by their effectiveness in treating a wide range of diseases, such as cancer, autoimmune disorders, and chronic inflammatory conditions. Additionally, the expiration of patents for biologic drugs has led to the emergence of biosimilars, which are highly similar versions of approved biologic drugs, offering cost-effective alternatives for patients and healthcare providers. As the demand for biologic drugs and biosimilars continues to rise, pharmaceutical companies are seeking reliable and scalable manufacturing partners to support their product development and commercialization efforts, thus fueling the growth of the biopharmaceutical contract manufacturing market.

Market Opportunity: Expansion into Advanced Therapies and Personalized Medicine

An opportunity in the biopharmaceutical contract manufacturing market lies in the expansion into advanced therapies and personalized medicine approaches, such as gene therapies, cell therapies, and personalized vaccines. These cutting-edge therapies hold immense promise for treating rare genetic disorders, cancers, and other debilitating conditions, offering targeted and curative treatment options for patients. However, the complex manufacturing processes, specialized infrastructure, and stringent regulatory requirements associated with advanced therapies pose challenges for pharmaceutical companies seeking to bring these therapies to market. By expanding their capabilities to support the manufacturing of advanced therapies and personalized medicine products, contract manufacturing organizations can capitalize on this emerging market opportunity and position themselves as strategic partners for biopharmaceutical companies engaged in innovative therapeutic development. This strategic expansion into advanced therapies and personalized medicine can drive further growth and diversification in the biopharmaceutical contract manufacturing segment, while also contributing to the advancement of novel treatments and patient care.

Biopharmaceutical Contract Manufacturing Market Share Analysis: Biosimilars

The Biosimilars segment within the Biopharmaceutical Contract Manufacturing Market is witnessing rapid growth. Biosimilars are biologic products that are highly similar to and have no clinically meaningful differences from an existing approved reference biologic product. They offer a cost-effective alternative to expensive branded biologics, providing increased access to essential therapies for patients while reducing healthcare expenditures. The demand for biosimilars is rising globally due to factors such as patent expirations of biologic drugs, escalating healthcare costs, and government initiatives to promote biosimilar adoption. Contract manufacturing organizations (CMOs) play a pivotal role in the development and production of biosimilars, offering expertise in process development, manufacturing, and regulatory compliance. As pharmaceutical companies seek to expand their biosimilar portfolios and capitalize on the growing market opportunities, they increasingly rely on CMOs to provide flexible and scalable manufacturing solutions. Additionally, the robust pipeline of biosimilar candidates across various therapeutic areas, including oncology, autoimmune diseases, and metabolic disorders, further drives the demand for contract manufacturing services. With the continued growth of the biosimilars market and the increasing outsourcing of biopharmaceutical manufacturing activities, the Biosimilars segment of the Biopharmaceutical Contract Manufacturing Market is poised for significant expansion.

Biopharmaceutical Contract Manufacturing Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbVie Inc, ADMA Biologics Inc, AGC Biologics Co. Ltd, Binex Co. Ltd, Boehringer Ingelheim GmbH, Cambrex Corp, Catalent Inc, FUJIFILM Diosynth Biotechnologies U.S.A. Inc, Inno Biologics Sdn Bhd, JRS Pharma LP, Lonza Group Ltd, Novartis AG, Pfizer Inc, ProBioGen AG, Rentschler Biopharma SE, Samsung Biologics Co. Ltd, Siegfried Holding AG, Thermo Fisher Scientific Inc, Toyobo Co. Ltd, WuXi Biologics Inc

Biopharmaceutical Contract Manufacturing Market Segmentation

By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Biopharmaceutical Contract Manufacturing Market Companies

AbbVie Inc
ADMA Biologics Inc
AGC Biologics Co. Ltd
Binex Co. Ltd
Boehringer Ingelheim GmbH
Cambrex Corp
Catalent Inc
FUJIFILM Diosynth Biotechnologies U.S.A. Inc
Inno Biologics Sdn Bhd
JRS Pharma LP
Lonza Group Ltd
Novartis AG
Pfizer Inc
ProBioGen AG
Rentschler Biopharma SE
Samsung Biologics Co. Ltd
Siegfried Holding AG
Thermo Fisher Scientific Inc
Toyobo Co. Ltd
WuXi Biologics Inc

Reasons to Buy the Biopharmaceutical Contract Manufacturing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Biopharmaceutical Contract Manufacturing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Biopharmaceutical Contract Manufacturing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Biopharmaceutical Contract Manufacturing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Biopharmaceutical Contract Manufacturing Market Size Outlook, $ Million, 2021 to 2030
3.2 Biopharmaceutical Contract Manufacturing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Biopharmaceutical Contract Manufacturing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Biopharmaceutical Contract Manufacturing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Biopharmaceutical Contract Manufacturing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Biopharmaceutical Contract Manufacturing Industry
4.2 Key Market Trends in Biopharmaceutical Contract Manufacturing Industry
4.3 Potential Opportunities in Biopharmaceutical Contract Manufacturing Industry
4.4 Key Challenges in Biopharmaceutical Contract Manufacturing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Biopharmaceutical Contract Manufacturing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Biopharmaceutical Contract Manufacturing Market Outlook by Segments
7.1 Biopharmaceutical Contract Manufacturing Market Outlook by Segments, $ Million, 2021- 2030
By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial

8 North America Biopharmaceutical Contract Manufacturing Market Analysis and Outlook To 2030
8.1 Introduction to North America Biopharmaceutical Contract Manufacturing Markets in 2024
8.2 North America Biopharmaceutical Contract Manufacturing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Biopharmaceutical Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial

9 Europe Biopharmaceutical Contract Manufacturing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Biopharmaceutical Contract Manufacturing Markets in 2024
9.2 Europe Biopharmaceutical Contract Manufacturing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Biopharmaceutical Contract Manufacturing Market Size Outlook by Segments, 2021-2030
By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial

10 Asia Pacific Biopharmaceutical Contract Manufacturing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Biopharmaceutical Contract Manufacturing Markets in 2024
10.2 Asia Pacific Biopharmaceutical Contract Manufacturing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Biopharmaceutical Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial

11 South America Biopharmaceutical Contract Manufacturing Market Analysis and Outlook To 2030
11.1 Introduction to South America Biopharmaceutical Contract Manufacturing Markets in 2024
11.2 South America Biopharmaceutical Contract Manufacturing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Biopharmaceutical Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial
12 Middle East and Africa Biopharmaceutical Contract Manufacturing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Biopharmaceutical Contract Manufacturing Markets in 2024
12.2 Middle East and Africa Biopharmaceutical Contract Manufacturing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Biopharmaceutical Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
ADMA Biologics Inc
AGC Biologics Co. Ltd
Binex Co. Ltd
Boehringer Ingelheim GmbH
Cambrex Corp
Catalent Inc
FUJIFILM Diosynth Biotechnologies U.S.A. Inc
Inno Biologics Sdn Bhd
JRS Pharma LP
Lonza Group Ltd
Novartis AG
Pfizer Inc
ProBioGen AG
Rentschler Biopharma SE
Samsung Biologics Co. Ltd
Siegfried Holding AG
Thermo Fisher Scientific Inc
Toyobo Co. Ltd
WuXi Biologics Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Biologics
Monoclonal Antibodies (MABs)
Recombinant Proteins
Vaccines
Antisense
RNAi & Molecular Therapy
Biosimilars
By Source
Mammalian
Non-Mammalian
By Service
Process Development
Fill And Finish Operations
Analytical And QC Studies
Packaging
By Application
Clinical
Commercial
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)